Clinical Trials Logo
  1. Home
  2. Liver Transplantation
  3. NCT00698399
  4. Details
NCT00698399 Clinical Trial

Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

Liver Transplant Clinical Trial

Official title:
Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00698399
Other study ID # 80237
Secondary ID
Status Completed
Phase N/A
First received June 12, 2008
Last updated February 27, 2018
Start date March 2008
Est. completion date February 2, 2010

Study information
Verified date February 2018
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.

Description:

The Departments of Anesthesiology are conducting an observational trial of markers in the serum of patients who are undergoing liver transplantation surgery. This study will utilize the biological markers, trimethylamine-N-oxide (TMAO), NGAL, and cystatin-C, sensitive markers of renal medullary injury in the blood and allantoin, a marker of oxidative stress as indicators of renal injury in a kidney during liver transplants. It is hypothesized that: (1) these markers are less pronounced in living donor liver transplant recipient patients than in cadaveric liver transplant recipients, and (2) these markers are less pronounced in cadaveric liver transplant recipients in which a "piggy-back" technique was used versus recipients in which a total venous occlusion technique was used. This study will be done in a multi-center format, along with researchers at UCSF

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date February 2, 2010
Est. primary completion date February 2, 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- American Society of Anesthesiologists (ASA) Class I-V.

- Patient is undergoing elective Liver Transplant Surgery.

- Patient is an adult, 18 years old or older.

Exclusion Criteria:

- Patients < 18 Years of Age

- Patients who are pregnant

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)
Lead Sponsor Collaborator
Vanderbilt University Medical Center University of California, San Francisco

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT01696331 - Text Messaging for Adherence in Adolescent Liver Transplant Recipients N/A
Recruiting NCT05051605 - Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
Recruiting NCT05940857 - Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
Completed NCT01598987 - Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. Phase 3
Active, not recruiting NCT05074160 - OCS Liver Perfusion (OLP) Post-Approval Registry
Completed NCT05087550 - Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
Recruiting NCT04836923 - LIFT Intervention in Liver Transplant Candidates N/A
Not yet recruiting NCT03666689 - Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
Not yet recruiting NCT06088758 - Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool N/A
Terminated NCT01230502 - Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation N/A
Completed NCT00171509 - Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients Phase 4
Not yet recruiting NCT06254248 - Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT06075745 - Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates Phase 2
Not yet recruiting NCT06280950 - Expanding Liver Transplant Immunosuppression Minimization Via Everolimus Phase 2
Completed NCT02057484 - A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
Active, not recruiting NCT03577431 - Liver Transplantation With Tregs at MGH Phase 1/Phase 2
Recruiting NCT06342557 - Transitional ePRO Diary Liver
Not yet recruiting NCT04265157 - Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant

External Links